Ações da SLS registam rali no primeiro semestre enquanto investidores de retalho se mantêm firmes durante o marco do julgamento AML
Sellas Life Sciences retail traders are largely refusing to cash out following a record H1 rally, with a Stocktwits poll showing 49% holding and 35% buying as the company's Phase 3 Regal trial in acute myeloid leukemia nears completion at 78 of 80 required events. SLS stock surged 292% in H1, surpassing its H1 2012 performance of 252%. Traders are focused on the final readout of the Regal trial testing GPS (galinpepimut-S) in AML, which requires 80 events to trigger final analysis. The rally com
SLS6,95%
LucasBennett·07-01 05:39









